Get started
Author

Mai Ha Bui

Observed names: M. H. Bui, Mai Bui, Mai H Bui, Mai H. Bui
OpenAlex ID: A5108377141
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer
2020 · Emily J. Faivre, Keith F. McDaniel, et al. · Nature · 412
Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor
2017 · Keith F. McDaniel, Le Wang, et al. · Journal of Medicinal Chemistry · 148
Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain
2020 · George S. Sheppard, Le Wang, et al. · Journal of Medicinal Chemistry · 140
Selective Chk1 inhibitors differentially sensitize p53‐deficient cancer cells to cancer therapeutics
2006 · Zehan Chen, Zhan Xiao, et al. · International Journal of Cancer · 129
PDF
Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies
2017 · Mai H. Bui, Xiaoyu Lin, et al. · Cancer Research · 124
Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus
2002 · Laurel S Almer, Virginia D Shortridge, et al. · Diagnostic Microbiology and Infectious Disease · 57
Anhydrolide Macrolides. 1. Synthesis and Antibacterial Activity of 2,3-Anhydro-6-O-methyl 11,12-Carbamate Erythromycin A Analogues
1998 · Richard L. Elliott, Daisy Pireh, et al. · Journal of Medicinal Chemistry · 42
Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia
2021 · Lu Zhang, Tianyu Cai, et al. · Molecular Cancer Therapeutics · 41
Comparative In Vitro Activity of ABT-773, a Novel Antibacterial Ketolide
2001 · A. M. Nilius, M. H. Bui, et al. · Antimicrobial Agents and Chemotherapy · 40
Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation
2017 · Jun Guo, Lloyd T. Lam, et al. · Biochemical and Biophysical Research Communications · 39
Novel AntibacterialClass
2003 · Peter J. Dandliker, Steve D. Pratt, et al. · Antimicrobial Agents and Chemotherapy · 34
Synthesis and SAR evaluation of oxadiazolopyrazines as selective Haemophilus influenzae antibacterial agents
2003 · Xenia Beebe, Angela M. Nilius, et al. · Bioorganic & Medicinal Chemistry Letters · 31
Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors
2008 · Zhan Xiao, John Xue, et al. · Biomarkers · 27
Preclinical Characterization of ABT-348, a Kinase Inhibitor Targeting the Aurora, Vascular Endothelial Growth Factor Receptor/Platelet-Derived Growth Factor Receptor, and Src Kinase Families
2012 · Keith B. Glaser, Junling Li, et al. · Journal of Pharmacology and Experimental Therapeutics · 22
From Bacterial Genomes to Novel Antibacterial Agents: Discovery, Characterization, and Antibacterial Activity of Compounds that Bind to HI0065 (YjeE) from Haemophilus influenzae
2007 · Claude G. Lerner, Philip J. Hajduk, et al. · Chemical Biology & Drug Design · 22
Synthesis and antibacterial activity of 6-O-arylpropargyl-9-oxime-11,12-carbamate ketolides
2004 · Xenia Beebe, Fan Yang, et al. · Bioorganic & Medicinal Chemistry Letters · 20
Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors
2018 · Steven D. Fidanze, Dachun Liu, et al. · Bioorganic & Medicinal Chemistry Letters · 13
Abstract 4718: ABBV-075, a novel BET family bromodomain inhibitor, represents a promising therapeutic agent for a broad spectrum of cancer indications
2016 · Aparna Sarthy, Leiming Li, et al. · Cancer Research · 10
Abstract 800: ABBV-744, a first-in-class and highly selective inhibitor of the second bromodomain of BET family proteins, displays robust activities in preclinical models of acute myelogenous leukemia
2018 · Xiaoyu Lin, Xiaoli Huang, et al. · Cancer Research · 7
Synthesis and antibacterial activity of 5-methoxy- and 5-hydroxy-6-fluoro-1,8-naphthyridone-3-carboxylic acid derivatives
2005 · T. Matthew Hansen, Yu-Gui Gu, et al. · Bioorganic & Medicinal Chemistry Letters · 7
Abstract 4738: The BET family bromodomain inhibitor ABBV-075 is a promising therapeutic agent for acute myeloid leukemia and myelodysplastic syndrome
2016 · Mai H. Bui, Xiaoyu Lin, et al. · Cancer Research · 3
Abstract 4695: Functional group elaboration of a low molecular weight fragment to yield the novel BET family bromodomain inhibitor ABBV-075
2016 · Keith McDaniel, Le Wang, et al. · Cancer Research · 1
Abstract A239: Preclinical characterization of ABT-348, a kinase inhibitor targeting the Aurora, VEGFR/PDGFR, and SRC kinase families.
2011 · Keith B. Glaser, Junling Li, et al. · Molecular Cancer Therapeutics · 1
Data from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia
2023 · Lu Zhang, Tianyu Cai, et al.
Data from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia
2023 · Lu Zhang, Tianyu Cai, et al.
Works count: 70
Citation count: 1,370
H-index: 16
I10-index: 18
Year
Topic
Type